COMPARISON OF DIFFERENT METHODS FOR EVALUATION CELLULAR IMMUNITY TO THE SARS-CoV-2 VIRUS

Most methods for evaluation T-cell immunity are laborious and unsuitable for routine laboratory diagnostics. This encourages researchers to create accessible and reproducible tests. The purpose of the study is to compare three methods for evaluation the level of cellular immune response to antigens of the SARS-CoV-2 virus in patients who have been ill and vaccinated against a new coronavirus infection. Examined: 26 people who had mild or moderate COVID-19 (group 1), 19 people vaccinated twice with Sputnik V, who did not have COVID-19 (group 2), 21 people who had COVID-19 and were twice vaccinated with Sputnik V (group 3) and 14 people who had COVID-19 twice (group 4). Peripheral blood mononuclear cells were isolated by gradient centrifugation. In the first method, mononuclear cells were incubated with the S-protein of the SARS-CoV-2 virus, stained with fluorescently labeled antibodies, the percentage of CD8highCD107a was counted on a BD FACS Canto II flow cytometer. When assessed by the ELISpot method on the “Human IFN-γ ELISpot” kit, IFN-γ production was stimulated by SARS-CoV-2 S-protein, or a mixture of SARS-CoV-2 protein peptides on the “Corona-T-test” kit. There were no significant differences in the level of expression of CD107a on CD8high in groups 1, 2, 3, and 4 and the number of IFN-γ producers per SARS-CoV-2 S-protein on the “Human IFN-γ ELISpot” kit. Production of IFN-γ is significantly lower in group 3 (hybrid immunity) 317.29±19.04 pg/ml than in groups 1 and 2 (post-infection and post-vaccination immunity) 454.95±20.32 and 470.77±26.24 pg /ml. The relative level of IFN-γ-producing cells in group 2 was higher (22.34±3.77) versus 16.83±2.35 in group 1 and 15.46±1.83 in group 3, the relative level of IFN- γ did not differ in these groups. Stimulation with full-length S-protein showed a significant reduction in the number of spots in group 4 (breakthrough immunity) 30.59±2.29 vs. 58.97±4.47 in group 3, and stimulation with a mixture of SARS-CoV-2 peptides in group 4 compared with group 3 revealed a significant increase in the number of IFN-γ-producing cells 86.72±7.20 versus 69.38±5.53 and IFN-γ production 991.25±65.18 pg/ml versus 760.76±50.70 pg/ml and in relative terms, 10.30±2.77 versus 8.61±2.66 and 68.10±9.41 versus 48.35±8.15, respectively. The results of three methods for evaluation the cellular immune response correlate positively with each other, but with different strengths

Результаты трехлетней вакцинации детей против пневмококковой инфекции в России

Background. After inclusion of pneumococcal vaccination in the National Vaccination Schedule, it is very important to evaluate the efficacy of routine immunisation of the child population for more than 3 years. The obtained results provide opportunity to analyse the problems in achieving the goal, determine their causes, and suggest the ways of overcoming. Our aim was to study the results of a three-year period of pneumococcal vaccination of children. Methods. The quality of immunoprophylaxis of pneumococcal infection in the territory of the Russian Federation were assessed by analysing the coverage of vaccination and timeliness of its conduct after the inclusion of pneumococcal vaccine in the National Vaccination Schedule. The actual epidemiological efficacy of pneumococcal vaccination was assessed based on morbidity and mortality due to community-acquired pneumonia, incidence of acute otitis media among children. By questioning parents (n = 352) who applied to the Federal State Autonomous Institution of the Russian Federation Ministry of Health ‘National Medical Research Centre for Children’s Health, the timeliness of pneumococcal vaccination for infants was established. Results. In most regions, a high level of pneumococcal vaccination coverage was reached (87% of children). Despite the fact that the majority of children (73%) were vaccinated untimely. In particular, the results of a questionnaire survey conducted in the Moscow vaccination centre indicate insufficient awareness of parents for the need to vaccinate infants against pneumococcal infection by primary care professionals and, as a consequence, a low level of timely initiated vaccine introduction (40.1%). The introduction of routine prophylactic pneumococcal vaccination in Russia resulted in a 35% reduction in the death rate of children from community-acquired pneumonia, led to a decrease in the incidence of acute otitis media. Conclusion. The introduction of routine prophylactic vaccination of children against Streptococcus pneumoniae helps to reduce morbidity and mortality from pneumococcal infections. The surveillance system for community-acquired pneumonia requires further improvement. It is advisable to conduct an additional analysis on the reasons for refusals and medical exemptions to vaccination. It is important to increase the professional level of paediatricians in prophylactic vaccination.Обоснование. После включения в Национальный календарь профилактических прививок вакцинации против пневмококковой инфекции очень важно оценить эффективность проводимой более 3 лет рутинной иммунизации детского населения. Полученные результаты позволят проанализировать проблемы в достижении цели, установить их причины и предложить пути преодоления. Цель исследования — изучить результаты трехлетнего периода вакцинации детей против пневмококковой инфекции. Методы. Проведена оценка качества иммунопрофилактики пневмококковой инфекции на территории Российской Федерации путем анализа охвата прививками, своевременности их проведения после включения пневмококковой вакцины в Национальный календарь профилактических прививок. Выполнена оценка фактической эпидемиологической эффективности вакцинации против пневмококковой инфекции на основании заболеваемости и смертности внебольничными пневмониями, заболеваемости острым средним отитом среди детского населения. Путем анкетирования родителей (n=352), обратившихся в ФГАУ «НМИЦ здоровья детей» Минздрава России, установлена своевременность вакцинации младенцев против пневмококковой инфекции. Результаты. В большинстве регионов достигнут высокий уровень охвата детей прививкой против пневмококковой инфекции (87%). При этом большинство детей (73%) были вакцинированы несвоевременно. В частности, результаты анкетирования, проведенного в центре вакцинации г. Москвы, указывают на недостаточную информированность родителей о необходимости вакцинации младенцев против пневмококковой инфекции специалистами первичного звена и, как следствие, низкий уровень своевременного начала введения вакцины (40,1%). Внедрение плановой вакцинопрофилактики против пневмококковой инфекции в России позволило на 35% снизить смертность детей от внебольничных пневмоний, привело к уменьшению заболеваемости острыми средними отитами. Заключение. Внедрение плановой вакцинопрофилактики детей против Streptococcus pneumoniae способствует снижению заболеваемости и смертности от пневмококковых инфекций. Система эпиднадзора за внебольничными пневмониями требует дальнейшего совершенствования. Целесообразно проведение дополнительного анализа причин отказов и медицинских отводов от вакцинации; важное значение имеет повышение профессионального уровня врачей-педиатров по вопросам вакцинопрофилактики.КОНФЛИКТ ИНТЕРЕСОВЛ.С. Намазова-Баранова — получение исследовательских грантов от фармацевтических компаний Пьер Фабр, Genzyme Europe B. V., ООО «Астра зенека Фармасьютикалз», Gilead / PRA «Фармасьютикал Рисерч Ассошиэйтс СиАйЭс», Teva Branded Pharma ceuti cal products R&D, Inc / ООО «ППД Девелопмент (Смоленск)», «Сталлержен С. А.» / «Квинтайлс ГезмбХ» (Австрия).М.В. Федосеенко — получение гонораров от компаний Pfizer, Sanofi Pasteur, MSD за чтение лекций.Остальные авторы статьи подтвердили отсутствие конфликта интересов, о котором необходимо сообщить

The Results of a Three-Year Pneumococcal Vaccination of Children in Russia

Background. After inclusion of pneumococcal vaccination in the National Vaccination Schedule, it is very important to evaluate the efficacy of routine immunisation of the child population for more than 3 years. The obtained results provide opportunity to analyse the problems in achieving the goal, determine their causes, and suggest the ways of overcoming. Our aim was to study the results of a three-year period of pneumococcal vaccination of children. Methods. The quality of immunoprophylaxis of pneumococcal infection in the territory of the Russian Federation were assessed by analysing the coverage of vaccination and timeliness of its conduct after the inclusion of pneumococcal vaccine in the National Vaccination Schedule. The actual epidemiological efficacy of pneumococcal vaccination was assessed based on morbidity and mortality due to community-acquired pneumonia, incidence of acute otitis media among children. By questioning parents (n = 352) who applied to the Federal State Autonomous Institution of the Russian Federation Ministry of Health ‘National Medical Research Centre for Children’s Health, the timeliness of pneumococcal vaccination for infants was established. Results. In most regions, a high level of pneumococcal vaccination coverage was reached (87% of children). Despite the fact that the majority of children (73%) were vaccinated untimely. In particular, the results of a questionnaire survey conducted in the Moscow vaccination centre indicate insufficient awareness of parents for the need to vaccinate infants against pneumococcal infection by primary care professionals and, as a consequence, a low level of timely initiated vaccine introduction (40.1%). The introduction of routine prophylactic pneumococcal vaccination in Russia resulted in a 35% reduction in the death rate of children from community-acquired pneumonia, led to a decrease in the incidence of acute otitis media. Conclusion. The introduction of routine prophylactic vaccination of children against Streptococcus pneumoniae helps to reduce morbidity and mortality from pneumococcal infections. The surveillance system for community-acquired pneumonia requires further improvement. It is advisable to conduct an additional analysis on the reasons for refusals and medical exemptions to vaccination. It is important to increase the professional level of paediatricians in prophylactic vaccination

EFFICIENCY OF USING THE ADAPTED GOAT’S MILK FORMULA IN THE DIET OF HEALTHY YOUNG INFANTS: A MULTICENTER PROSPECTIVE COMPARATIVE STUDY

Background. There is no doubt that it is necessary to study the efficiency of milk formulas that are introduced into the Russian market of baby food. This applies to both new products and known brands of formulas whose composition is subject to change.Objective. Our aim was to assess the clinical efficacy of the adapted goat's milk formula in the diet of young infants.Methods. We conducted a prospective comparative study with healthy full-term  children aged 0–5 months being on a formula (main group) or breast feeding (comparison group). The tolerability of the adapted goat's milk formula, the dynamics of anthropometric indicators, changes in body composition as well as microscopic characteristics  of stool and general clinical and biochemical parameters  of peripheral blood were assessed after 1 month.Results. Good tolerability of the goat's milk formula was noted in 184 (96.8%) of 190 children in the main group. In the course of taking the product, the proportion of children with functional disorders of the gastrointestinal tract decreased significantly from 57 (30%) to 27 (14%) (p < 0.001). Physical development,  complete blood count results, the levels of ferritin, prealbumin and 25(OH)D in children of the main group and the comparison group (n = 71) were comparable and were within the mean age parameters. Qualitative analysis of the level of specific IgE to goat's milk proteins did not reveal any sensibilization in any of the children receiving the milk formula, either at the beginning of the study or after 1 month of taking the product.Conclusion. The studied adapted goat's milk formula can be used in nutrition of young infants in cases of lack or absence of mother's milk